Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 7/20 | 0.71 |
| ▸ | MGMT | P16455 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968920 | 0.83 | PIN1 (1.00) | PIN1MGMT | |
| SCHEMBL3309544 | 0.78 | MGMT (1.00) | PIN1MGMTMAPTCDK1CCNB1 | |
| SCHEMBL7752283 | 0.77 | MGMT (0.55) | PIN1MGMTMAPTCDK1CCNB1 | |
| SCHEMBL8798119 | 0.77 | PIN1 (0.63) | PIN1MGMTMAPTMEN1NPC1 | |
| SCHEMBL30112419 | 0.77 | PIN1 (0.63) | PIN1MGMTMEN1NPC1RAB9A | |
| SCHEMBL20278132 | 0.76 | PIN1 (0.61) | PIN1MGMTMAPTMEN1NPC1 | |
| SCHEMBL4651284 | 0.76 | PIN1 (0.69) | PIN1MGMTMAPTMEN1NPC1 | |
| SCHEMBL4068099 | 0.76 | MGMT (0.76) | PIN1MGMTCDK1CCNB1CCNA2 | |
| SCHEMBL27771143 | 0.75 | PIN1 (0.57) | PIN1MGMTMEN1NPC1RAB9A | |
| SCHEMBL8567785 | 0.75 | PIN1 (0.53) | PIN1MGMTMAPTMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-10-02 | — | — | US | claimed |
| US-8791081-B2 | MGMT inhibitor combination for the treatment of neoplastic disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-29 | — | — | US | claimed |
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | LIU LILI | 2010-04-15 | — | — | US | claimed |
| CN-101380297-A | Compound platinum medicine sustained-release agent | JINAN SHUAIHUA PHARMACEUTICAL (CN) | 2009-03-11 | — | — | CN | claimed |
| WO-2008109417-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-09-12 | — | — | WO | claimed |
| CN-101254170-A | An anticancer sustained release injection carrying clorfarabine and its synergist | JINAN KANGQUAN PHARMACEUTICAL (CN) | 2008-09-03 | — | — | CN | claimed |
| CN-101244034-A | Sustained-release agent containing taxone and its synergistic agent | JINAN KANGQUAN PHARMACEUTICAL (CN) | 2008-08-20 | — | — | CN | claimed |
| CN-100386115-C | Anti-cancer medicine composition | QINGZHONG KONG (CN) | 2008-05-07 | — | — | CN | claimed |
| CN-101023922-A | Anti-cancer sustained-release agent carrying glucocorticoid hormone and chemotherapeutic drug | KANGQUAN MEDICINE SCIENCE TECH (CN) | 2007-08-29 | — | — | CN | claimed |
| CN-101002730-A | Compounding anticarcinogen containing neovascular-inhibitor | SHUAIHUA MEDICAL TECH CO LTD J (CN) | 2007-07-25 | — | — | CN | claimed |
| CN-1846687-A | Slow-release agent containing taxane and synergist thereof | JINAN KANGQUAN MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1846673-A | Slow-released anticancer medicine prepn containing pyrimidine medicine | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1846679-A | Sustained-release injection containing methotrexate and synergist thereof | JINAN SHUAIHUA MEDICINE SCI TE (CN) | 2006-10-18 | — | — | CN | claimed |
| CN-1733300-A | Anticancer implantation agent | KONG QINGZHONG (CN) | 2006-02-15 | — | — | CN | claimed |
| CN-1628853-A | Anti-cancer medicine composition | KONG QINGZHONG (CN) | 2005-06-22 | — | — | CN | claimed |
| EP-1142893-B1 | Substituted 6(4)-benzyloxypyrimidines | US HEALTH (US) | 2004-12-29 | — | — | EP | claimed |
| US-20020013299-A1 | Substituted O6-benzyl-8-aza-guanines | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-01-31 | — | — | US | claimed |
| EP-1142893-A1 | Substituted O6-benzylguanines and 6(4)-benzyloxypyrimidines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2001-10-10 | — | — | EP | claimed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | claimed |
| WO-1996004281-A1 | SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093647-A1 | MGMT INHIBITOR COMBINATION FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | PIN1 2059/4885MGMT 1/4885MAPT 2581/4885 |
| US-20020013299-A1 | Substituted O6-benzyl-8-aza-guanines | OGG1, UNG, AGT | PIN1 4212/4885MGMT 4/4885MAPT 4683/4885 |
| US-20140296264-A1 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS | MGMT, MSH2, UNG | PIN1 1953/4885MGMT 1/4885MAPT 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.